DiaMedica Therapeutics (DMAC) to Release Quarterly Earnings on Wednesday

DiaMedica Therapeutics (NASDAQ:DMAC) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, November 13th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties that wish to register for the company’s conference call can do so using this link.

DiaMedica Therapeutics Stock Up 2.9 %

DiaMedica Therapeutics stock opened at $4.30 on Monday. The company’s fifty day simple moving average is $4.27 and its 200-day simple moving average is $3.53. DiaMedica Therapeutics has a 12 month low of $2.12 and a 12 month high of $4.95. The stock has a market cap of $183.82 million, a P/E ratio of -8.11 and a beta of 1.46.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. HC Wainwright assumed coverage on shares of DiaMedica Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $7.00 price objective for the company. Oppenheimer reaffirmed an “outperform” rating and issued a $6.00 price objective on shares of DiaMedica Therapeutics in a research note on Friday, August 16th.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.